Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 5/20 | 0.52 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.42 |
| ▸ | SUCNR1 | Q9BXA5 | 3/20 | 0.40 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.40 |
| ▸ | CLIC1 | O00299 | 1/20 | 0.40 |
| ▸ | CLCN2 | P51788 | 1/20 | 0.40 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.40 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.40 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.40 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.40 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.40 |
| ▸ | TTR | P02766 | 1/20 | 0.40 |
| ▸ | ALB | P02768 | 1/20 | 0.40 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.40 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19475173 | 0.79 | PTGS2 (0.55) | PTGS2FFAR1SUCNR1CXCL8CLIC1 | |
| SCHEMBL9447453 | 0.78 | PTGS2 (0.54) | PTGS2FFAR1SUCNR1CXCL8CLIC1 | |
| SCHEMBL5151907 | 0.76 | SUCNR1 (0.48) | PTGS2FFAR1SUCNR1PTGS1NR1H4 | |
| SCHEMBL11899242 | 0.74 | PTGS1 (0.50) | PTGS2FFAR1SUCNR1AKR1B1PTGS1 | |
| SCHEMBL5518653 | 0.72 | NLRP3 (0.57) | PTGS2TDP1POLB | |
| SCHEMBL5852133 | 0.72 | SUCNR1 (0.44) | PTGS2SUCNR1NR3C2 | |
| SCHEMBL9724473 | 0.72 | CXCL8 (0.57) | PTGS2SUCNR1CXCL8AKR1B1AKR1B10 | |
| SCHEMBL228994 | 0.71 | PTGS2 (0.57) | PTGS2AKR1B1PTGS1TDP1 | |
| Methylamine SCHEMBL11468456 | 0.71 | CTBP2 (0.58) | PTGS2CXCL8CLIC1CLCN2AKR1B1 | |
| SCHEMBL29363967 | 0.71 | PTGS2 (0.57) | PTGS2AKR1B1PTGS1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1265606-B9 | CELL ADHESION INHIBITORS | BIOGEN IDEC INC (US) | 2007-02-28 | — | — | EP | disclosed |
| EP-1741428-A2 | Cell adhesion inhibitors | Biogen Idec MA, Inc. (US) | 2007-01-10 | — | — | EP | disclosed |
| EP-1265606-B1 | CELL ADHESION INHIBITORS | BIOGEN IDEC INC (US) | 2006-10-25 | — | — | EP | disclosed |
| US-20060166961-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2006-07-27 | — | — | US | disclosed |
| US-7034043-B2 | Cell adhesion inhibitors | BIOGEN IDEC MA INC. (US) | 2006-04-25 | — | — | US | disclosed |
| EP-1091943-B1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | PFIZER PROD INC (US) | 2005-11-30 | — | — | EP | disclosed |
| US-20040132809-A1 | Cell adhesion inhibitors | BIOGEN, INC. | 2004-07-08 | — | — | US | disclosed |
| US-6630503-B1 | Non-peptidic sulfonamide compounds that specifically inhibit the binding of ligands to VLA-4 for inhibition, prevention and suppression of VLA-4-mediated cell adhesion and pathologies such as inflammation and immune reactions | BIOGEN, INC. | 2003-10-07 | — | — | US | disclosed |
| EP-1265606-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 2002-12-18 | — | — | EP | disclosed |
| EP-1265606-A4 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6355662-B1 | PEPTIDE AND NONPEPTIDES AUTOIMMUNE DISEASES, ANTIINFLAMMATORY AGENTS | PFIZER INC | 2002-03-12 | — | — | US | disclosed |
| US-6306887-B1 | AROMATIC UREAS, CARBAMATES AND TRIAMINONITRILES AND HETEROCYCLIC COMPOUNDS | PFIZER INC | 2001-10-23 | — | — | US | disclosed |
| EP-1091943-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | Pfizer Products Inc. (US) | 2001-04-18 | — | — | EP | disclosed |
| WO-2001012186-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 2001-02-22 | — | — | WO | disclosed |
| WO-2000000477-A1 | NON-PEPTIDYL INHIBITORS OF VLA-4 DEPENDENT CELL BINDING USEFUL IN TREATING INFLAMMATORY, AUTOIMMUNE, AND RESPIRATORY DISEASES | PFIZER PRODUCTS INC. (US) | 2000-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040132809-A1 | Cell adhesion inhibitors | VCAM1, ICAM1, EPCAM | PTGS2 3907/4885FFAR1 552/4885SUCNR1 891/4885 |
| US-20060166961-A1 | Cell adhesion inhibitors | VCAM1, ICAM1, EPCAM | PTGS2 3444/4885FFAR1 743/4885SUCNR1 2180/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.